Type 2 Diabetes

When most people think about diabetes, they picture the pancreas, insulin, or blood sugar. However, researchers are increasingly asking a different question: what if another organ has been quietly influencing glucose metabolism all along? Surprisingly, the answer may be the skeleton. For decades, bone was viewed primarily as the body’s …

Diabetes often develops silently for years before blood sugar levels become high enough for a diagnosis. What if tiny biological packages circulating in the bloodstream could reveal those hidden changes long before symptoms appear? Researchers are increasingly studying how exosomes may serve as biomarkers for diabetes because these microscopic messengers …

Managing diabetes has never offered more therapeutic options. Continuous glucose monitors (CGMs), automated insulin delivery systems, GLP-1 receptor agonists, SGLT2 inhibitors, and individualized treatment plans have transformed patient care. Yet despite these advances, many people with diabetes continue to struggle, not because treatments are ineffective, but because the overall workload …

Diabetes is often diagnosed only after blood sugar levels have already risen above normal. However, what if the earliest warning signs appeared years before glucose levels changed? That question is driving exciting research into metabolomics, a rapidly growing field that analyzes tiny molecules produced during normal metabolism. Instead of focusing …

Diabetes research has advanced rapidly over the past two decades, leading to groundbreaking medications such as GLP-1 receptor agonists, SGLT2 inhibitors, and dual incretin therapies. However, one challenge remains constant: developing new treatments through traditional clinical trials is often expensive, time-consuming, and inflexible. Could there be a better way to …

Imagine prescribing the same diabetes medication to two patients with nearly identical A1C levels, only to see one achieve excellent glycemic control while the other experiences little benefit or troublesome side effects. This scenario is common in diabetes care and highlights an important question: could genetics explain these differences? Growing …

For many years, C-peptide testing was viewed as a simple tool to distinguish type 1 diabetes from type 2 diabetes. However, the story has changed. As researchers gain a better understanding of pancreatic beta-cell function, C-peptide testing in diabetes has become much more valuable than a diagnostic aid alone. Today, …

Not long ago, diabetes management focused primarily on controlling blood glucose levels. Today, that approach has evolved dramatically as cardiologists and endocrinologists increasingly work together to reduce cardiovascular risk. Thanks to groundbreaking cardiovascular outcome trials (CVOTs), clinicians now understand that treating type 2 diabetes means protecting the heart, kidneys, and …

For years, glucagon-like peptide-1 (GLP-1) receptor agonists have dominated conversations about diabetes and obesity treatment. However, another hormone is quietly returning to the spotlight. Amylin diabetes therapy is making a comeback as researchers develop a new generation of drugs designed to improve blood glucose control and support weight management. Amylin …

For years, the treatment of diabetic kidney disease focused primarily on glycemic control and blood pressure management. More recently, SGLT2 inhibitors and GLP-1 receptor agonists have transformed the landscape by reducing kidney disease progression and cardiovascular events. However, another therapeutic class is rapidly gaining recognition. Non-steroidal mineralocorticoid receptor antagonists (MRAs) …